229910052757 nitrogen Inorganic materials 0.000 claims description 15.229910052799 carbon Inorganic materials 0.000 claims description 15.UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 20.125000003545 alkoxy group Chemical group 0.000 claims description 25. 150000002367 halogens Chemical group 0.000 claims description 28.229910052736 halogen Inorganic materials 0.000 claims description 28.125000000592 heterocycloalkyl group Chemical group 0.000 claims description 30.239000008194 pharmaceutical composition Substances 0.000 claims description 38.239000011780 sodium chloride Substances 0.000 claims description 39.229910052739 hydrogen Inorganic materials 0.000 claims description 40.125000001424 substituent group Chemical group 0.000 claims description 66. 125000000217 alkyl group Chemical group 0.000 claims description 70.125000001072 heteroaryl group Chemical group 0.000 claims description 78.125000003118 aryl group Chemical group 0.000 claims description 88.108010064862 Nicotinamide Phosphoribosyltransferase Proteins 0.000 title abstract description 15.102000015532 Nicotinamide Phosphoribosyltransferase Human genes 0.000 title abstract description 15.239000000203 mixture Substances 0.000 title abstract description 41.230000002401 inhibitory effect Effects 0.000 title abstract description 46.150000001875 compounds Chemical class 0.000 title claims abstract description 186.Assignors: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY Publication of US20200247795A1 publication Critical patent/US20200247795A1/en Application granted granted Critical Publication of US11078195B2 publication Critical patent/US11078195B2/en Status Active legal-status Critical Current Adjusted expiration legal-status Critical Links ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAN, GYOON HEE, KIM, HYUN SEOK Assigned to CHECKMATE THERAPEUTICS INC. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from US201662309557P external-priority Application filed by Checkmate Therapeutics Inc filed Critical Checkmate Therapeutics Inc Priority to US16/085,774 priority Critical patent/US11078195B2/en Assigned to INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY reassignment INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Original Assignee Checkmate Therapeutics Inc Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) ( en Inventor Hyun Seok Kim Gyoon Hee Han Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Granted Application number US16/085,774 Other versions US11078195B2 Google Patents Novel compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing sameÄownload PDF Info Publication number US20200247795A1 US20200247795A1 US16/085,774 US201716085774A US2020247795A1 US 20200247795 A1 US20200247795 A1 US 20200247795A1 US 201716085774 A US201716085774 A US 201716085774A US 2020247795 A1 US2020247795 A1 US 2020247795A1 Authority US United States Prior art keywords group nicotinamide benzyl compound chemical formula Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents US20200247795A1 - Novel compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same US20200247795A1 - Novel compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |